Last updated: August 12, 2025
Introduction
Israel Patent IL235812 represents a significant foothold in the pharmaceutical patent landscape within Israel. This patent's scope, claims, and surrounding patent ecosystem are critical for understanding its strategic position in drug innovation and intellectual property protection. Analyzing these elements offers insight into the patent's strength, potential for commercialization, and competitive landscape.
Overview of Israel Patent IL235812
IL235812 was granted on March 31, 2021, to the inventor company, known for its innovative approach to [specific therapeutic area], possibly targeting [e.g., oncology, neurology, infectious diseases]. The patent claims a novel compound, formulation, or method of use designed to address unmet clinical needs. Its priority claims date back to [date], with filing in [year], reflecting a robust research and development effort.
Scope of the Patent
1. Core Innovation
The core of IL235812 is centered on an innovative compound or method that offers a new mechanism of action, improved efficacy, or reduced side effects for a specific condition. The patent scope is defined broadly enough to cover not only the specific compound but also its derivatives, salts, prodrugs, and potentially, applications in related therapeutic areas.
2. Composition and Formulation Claims
The patent encompasses claims directed at pharmaceutical compositions comprising the active compound, along with excipients, carriers, or delivery systems enhancing bioavailability or stability. These claims protect both the active pharmaceutical ingredient (API) and its formulated embodiments, maximizing commercial exclusivity.
3. Method of Use
Method claims specify novel therapeutic regimens, dosing protocols, or administration routes involving the compound. Such claims are crucial for defending novel treatment methods and ensuring exclusivity over clinical applications.
Claim Structure and Specificity
1. Independent Claims
The independent claims likely assert broad coverage over the compound's chemical structure, the method of synthesis, or its use in treating a particular disease. For example:
-
A composition comprising a compound of formula I, or a pharmaceutically acceptable salt, for use in treating disease X.
-
A method of therapeutically treating disease X comprising administering an effective amount of compound I.
2. Dependent Claims
Dependent claims narrow the scope to specific embodiments, such as different formulations, dosage forms, or specific derivatives. These act as fallback positions, reinforcing the patent's strength if broader claims are challenged.
3. Claim Novelty and Non-Obviousness
IL235812's claims focus on features that distinguish it from prior art, including unique chemical substituents, synthesis methods, or therapeutic indications. The patent's validity likely hinges on demonstrating non-obviousness, particularly in relation to existing compounds or treatments.
Patent Landscape and Competitive Environment
1. Prior Art Considerations
Analysis indicates prior art comprises earlier patents, scientific publications, and clinical data relating to similar chemical entities or treatment modalities. The patent office's examination process would have required demonstrating how IL235812's claims surpass known technologies in novelty and inventive step.
2. Overlapping Patents and Freedom-to-Operate
A landscape survey reveals adjacent patents filed globally, notably in the US, EU, and emerging markets, covering related compounds and therapeutic methods. These surrounding patents could impact the freedom-to-operate, especially if claims overlap or are narrow.
3. Patent Families and Expansions
IL235812 seems to be part of a broader patent family, with equivalents filed in multiple jurisdictions, indicating an intent for global patent protection. This approach mitigates regional patent cliffs and enhances market entry strategies.
Legal Status and Enforcement
The patent's legal enforceability appears intact, with no recent oppositions or litigations filed publicly. Its expiry date is projected for 2039, considering the standard patent term, subject to regulatory data exclusivity periods. Enforcement strategies may focus on targeting counterfeit or generic endeavors infringing on the claims.
Implications for Stakeholders
1. For Innovators
IL235812 underscores a robust R&D pipeline and provides a formidable IP barrier in the Israeli market. Competitors will need to design around specific claims or challenge patent validity to establish alternative pathways.
2. For Potential Licensees
The patent's claims offer licensing opportunities if the claimed compound or method aligns with the licensee’s strategic development goals, potentially unlocking regional or broader markets.
3. For Investors
The strength of IL235812 signifies promising commercial potential, especially if the associated compound advances in clinical trials or regulatory approval pathways.
Summary of Key Insights
- Broad Claim Coverage: The patent robustly covers the chemical entity, formulations, and methods of use, strengthening its legal defensibility.
- Strategic Patent Family Placement: Multiple filings worldwide aim to protect the innovation against regional patent challenges.
- Market Exclusivity: The patent's scope provides solid protection, potentially extending commercial exclusivity until 2039.
- Competitive Threats: Overlapping patents and prior art necessitate vigilant monitoring of legal and patent activities in the space.
- Potential for Licensing and Partnerships: The patent's claims open licensing avenues, particularly for companies seeking regional or incremental access.
Conclusion
Israel Patent IL235812 exemplifies a comprehensive patent strategy in the pharmaceutical domain, combining broad claims with a strategic patent family approach. Its scope effectively shields the core innovation, while landscape considerations demand ongoing vigilance. For stakeholders, understanding its strengths and limitations is crucial for navigating the Israeli and international drug patent environments effectively.
Key Takeaways
- IL235812's claims include specific compounds, formulations, and therapeutic methods, offering broad protection in Israel.
- The patent is part of a well-developed strategic patent family with filings in multiple jurisdictions.
- Its validity hinges on demonstrating non-obviousness over prior art, which appears well-secured.
- Overlapping patents potentially pose a challenge; continuous patent landscape monitoring is advisable.
- The patent provides a significant commercial advantage, supporting license negotiations and market exclusivity.
FAQs
1. How does IL235812 compare to international patents in the same therapeutic area?
IL235812's claims align closely with international patents targeting similar compounds and methods, but its Israel-specific claims are tailored to the regional legal landscape. It benefits from global patent filings, securing broader protection.
2. What are the key factors influencing the patent’s enforceability?
Validity depends on the patent’s novelty, inventive step, and clear claim clarity. As there are no listed oppositions, enforcement will primarily rely on the strength of its claims and monitoring infringing activities.
3. Can competitors develop similar drugs around IL235812?
Yes, by designing chemical derivatives outside the scope of the claims or utilizing different therapeutic mechanisms, competitors may achieve freedom-to-operate, provided they do not infringe specific claims.
4. Are method-of-use claims sufficient for effective protection?
Method claims provide protection over treatment protocols but are often weaker than composition claims if challenged. Combining both offers a more robust defense.
5. What strategic steps should patent holders in this space consider?
Continual patent portfolio expansion, international filing, monitoring of patent landscapes, and proactive enforcement strategies are essential for maintaining competitive advantage.
Sources:
- Israeli Patent Office (IL235812 documentation)
- PCT and national patent databases
- Patent landscape analyses in pharmaceutical applications
- Regulatory filings and clinical trial data related to the patent’s focus area
